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The dengue virus (DENV) complex is composed of
four distinct but serologically related flaviviruses,
which together cause the present-day most impor-
tant emerging viral disease. Although DENV infection
induces lifelong immunity against viruses of the
same serotype, the antibodies raised appear to
contribute to severe disease in cases of heterotypic
infections. Understanding the mechanisms of DENV
neutralization by antibodies is, therefore, crucial for
the design of vaccines that simultaneously protect
against all four viruses. Here, we report a compara-
tive, high-resolution crystallographic analysis of an
‘‘A-strand’’ murine monoclonal antibody, Mab 4E11,
in complex with its target domain of the envelope
protein from the four DENVs. Mab 4E11 is capable
of neutralizing all four serotypes, and our study
reveals the determinants of this cross-reactivity.
The structures also highlight the mechanism by
which A-strand Mabs disrupt the architecture of the
mature virion, inducing premature fusion loop expo-
sure and concomitant particle inactivation.
INTRODUCTION
The four serotypes of dengue virus (DENV) constitute the largest
vector-borne viral disease burden in the developing world
(Monath, 1994), with 50–100million cases reported yearly. ThereStructure 20, 30is neither approved vaccine nor specific therapy to fight these
infections. Dengue fever (DF), the most common form of dengue
disease, is an acute febrile illness and is generally nonlethal.
However, about 1% of DF cases evolve into severe forms,
such as life-threatening dengue hemorrhagic fever (DHF) or
dengue shock syndrome (DSS) (Mackenzie et al., 2004). Infec-
tion by DENV raises lifelong immunity against the infecting sero-
type (Sabin, 1952), but only transient protection against the other
serotypes. In the long term, subsequent infections by viruses
from a different DENV serotype are associated with a greater
risk for DHF/DSS (Sangkawibha et al., 1984). A likely explanation
is that weakly neutralizing, serotype cross-reactive antibodies
present in such patients can mediate viral uptake by—and
enhanced infection of—cells bearing Fcg receptors (Halstead
and O’Rourke, 1977), a phenomenon termed antibody-depen-
dent enhancement (ADE) of infection.
DENV is a member of the flavivirus genus of the Flaviviridae
family, which includes several other important human pathogens
such as Japanese encephalitis (JE), West Nile (WN), yellow fever
(YF), and tick-borne encephalitis (TBE) viruses (Lindenbach
et al., 2007). The virus particles are enveloped by a lipid bilayer
that is enclosed within an icosahedral scaffold formed by the
envelope glycoprotein E (Kuhn et al., 2002) (Figure 1). The virions
enter cells by receptor-mediated endocytosis followed by low
pH-induced fusion of the viral and endosomal membranes (van
der Schaar et al., 2008). The E glycoprotein is both responsible
for receptor binding and for inducing membrane fusion in the
endosome, and is thus the main player in the flavivirus entry
process. Flavivirus E is about 500 amino acids long and is
anchored in the viral membrane by two C-terminal transmem-
brane (TM) helices. A soluble fragment of E, containing roughly
the 400 N-terminal amino acids of E, has been crystallized3–314, February 8, 2012 ª2012 Elsevier Ltd All rights reserved 303
Figure 1. Overview of the DENV Envelope Protein and Its Complexes with scFv 4E11
(A) Crystal structure of the prefusion DENV-2 sE dimer (PDB accession number 1OKE). One E subunit is highlighted colored by domains (DI, red; DII, yellow; DIII,
blue). The fusion loop (residues 100–108) is colored green. The arrows indicate the view zoomed in (B).
(B) Close-up showing DIII from one subunit in the sE dimer and its orientation with respect to the viral membrane in the mature virion. Note the proximity of the
fusion loop of the partner subunit (in the forefront, yellow and green).
(C) The icosahedral glycoprotein shell of themature DENV-2 virion formed by 90 E dimers, docked into a 9.5 A˚ resolution cryo-EM reconstruction (PDB accession
number 1THD). Each E subunit is colored according to domains, as in (A). View down an icosahedral 3-fold axis (central gray triangle). Icosahedral 5- and 2-fold
axes of the particle are marked with pentagons and ovals, respectively.
(D) Amino acid sequence alignment of DIII from the four DENV strains used in this study (listed in Table 1). Residue numbers correspond to the full-length DENV-1
E protein (the numbering for DENV-3 DIII is shifted by two residues). Strictly and semiconserved residues are highlighted in red and yellow, respectively. b Strands
are labeled above the sequence with blue arrows. Epitope residues are marked with asterisks.
(E) Overview of the structure of DENV-1 DIII (dark blue) in complex with scFv 4E11. The heavy-/light-chain framework regions are dark/light gray, respectively,
with the CDR loops color coded and labeled H1-H3 and L1-L3.
(F and G) Superposition of the scFvs (F) and DIIIs (G) from the four complexes. The scFv 4E11 molecules were superposed using the framework region residues.
Residues at the antibody-antigen interface are labeled according to the Kabat scheme (Kabat et al., 1991) and shown in ball and stick (oxygen, red; nitrogen, dark
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Determinants of Dengue Virus Cross-Neutralization(Modis et al., 2003, 2005; Rey et al., 1995; Zhang et al., 2004). Its
structure features three distinct domains (Figure 1A). DI, which
contains the N terminus, is at the center, with DII and DIII at either
side. DII displays a hydrophobic fusion loop—the amino acid
sequence of which is conserved across flaviviruses—at its
distal-most tip. The fusion loop inserts into the endosomal
membrane during an acid-pH-driven membrane-fusogenic
conformational change. This process is necessary to release
the viral nucleic acid within the cytoplasm to initiate infection.
DIII, the C-terminal portion of the ectodomain, is an eight-
stranded b sandwich (strands labeled A–G, Figure 1B) with an
immunoglobulin superfamily fold. DIII is thought to be involved
in receptor binding (Crill and Roehrig, 2001), although the nature
of the relevant receptor(s) at the surface of susceptible cells is
not known despite intensive studies (Lindenbach et al., 2007).
Infectious dengue virions derive from proteolytic activation
of noninfectious immature particles, the surface of which is
composed of heterodimers of the viral glycoproteins prM and E
(Lindenbach et al., 2007). Cleavage by furin or other proteases
eliminates the N-terminal half of prM (the ‘‘pr’’ domain’’). This
maturation step is often incomplete, resulting in a significant
fraction of only partially mature virions released from infected
cells (Junjhon et al., 2010). These virons are infectious and
have been shown to display both mature- and immature-like
patches on the same virion (Plevka et al., 2011), displaying anti-
genic characteristics of both types (Nelson et al., 2008).
The human humoral immune response to DENV is dominated
by cross-reactive antibodies, many of which are non-neutralizing
and target prM (Crill et al., 2009; Dejnirattisai et al., 2010; Lai
et al., 2008; Oliphant et al., 2007). The resulting antigenic hetero-
geneity of DENV appears to increase the potential for ADE
(Cherrier et al., 2009). Identifying the epitopes on the E protein
that are targeted by potent, broadly neutralizing antibodies,
ideally neutralizing simultaneously all four dengue serotypes, is
therefore important for vaccine design.
A recent study on memory B cells recovered from DENV-
infected individuals revealed the presence of clones encoding
Mabs binding to DIII, which potently neutralize multiple sero-
types (Beltramello et al., 2010). Cross-neutralizing Mabs target-
ing DIII are also a well-characterized component of the murine
immune response to DENV. Biochemical studies showed their
epitopes to be clustered on the DIII A strand (Gromowski et al.,
2008, 2010; Lisova et al., 2007; Matsui et al., 2009; Shrestha
et al., 2010; Sukupolvi-Petty et al., 2007; Thullier et al., 2001).
These ‘‘A-strand’’ Mabs are believed to neutralize mainly by
interfering with attachment to host cells (Crill and Roehrig,
2001; Thullier et al., 2001). The crystal structure of the Fab frag-
ment of an A-strand antibody, Mab 1A1D-2, has been deter-
mined in complex with recombinant DIII to 3 A˚ resolution, and
the structure was docked into a low-resolution cryo-EM recon-
struction of the DENV-2 particle in complex with the same Fab
(Lok et al., 2008). This study indicated that binding of 1A1D-2
disrupts the organization of the particle. Binding of Fab 1A1D-2blue) with carbon atoms following the main-chain color scheme. The relevant DIII
text) is highlighted in yellow. The views correspond approximately to an ‘‘open bo
to the orientation in (B).
See also Table S1.
Structure 20, 30to the mature DENV-2 virion was shown to be temperature
sensitive, reflecting the partially occluded nature of the epitope,
and its transient exposure through a ‘‘breathing’’ motion of the
particle.
Mab 1A1D-2 was raised against DENV-2 strain NGC and
neutralizes DENV-2, DENV-1, and DENV-3 (in order of
decreasing efficacy) but does not neutralize DENV-4 (Roehrig
et al., 1998). To our knowledge, the determinants of its cross-
reactivity have, however, not been investigated. We approach
here this issue by analyzing the murine Mab 4E11 (Megret
et al., 1992), which also binds to the DIII A strand (Lisova et al.,
2007) and neutralizes all four DENV serotypes (Thullier et al.,
1999). We report the crystal structures of a recombinant
single-chain variable fragment (scFv) of 4E11 in complex with
DIII from all four serotypes to high resolution (1.6–2.1 A˚). Our
study reveals the basis for serotype-dependent variations in
binding affinity and neutralization efficacy, and provides insights
into the immunodominance of the DIII A strand in mice. In partic-
ular, our study, together with the studies on Mab 1A1D-2
mentioned above, supports a neutralization mechanism for
A-strand antibodies that explains how 4E11 can neutralize all
four serotypes with IC50 varying between 1 and 100 nM, despite
about more than five orders of magnitude difference in Fab/DIII
binding affinities across serotypes.
RESULTS AND DISCUSSION
Characterization of Mab 4E11
Competition ELISA experiments were carried out to determine
the affinity, at equilibrium and in solution, between recombinant
Fab 4E11 and isolated DIII from each of the clinical isolates of
DENV listed in Table 1, spanning all four serotypes. The results
show that Fab 4E11 binds with nanomolar affinity to DIII from
DENV-1, DENV-2, and DENV-3 (in this order), and with only
micromolar affinity to DENV-4 DIII. The ratio of affinities, in the
order DENV-1:DENV-2, DENV-2:DENV-3, and DENV-3:DENV-4,
is 1:5, 1:20, and 1:500, respectively, resulting in a 1:50,000 ratio
between DENV-1 and DENV-4. Table 1 also reports the Mab
4E11 concentration corresponding to 50% neutralization
(IC50) of each of the corresponding DENV isolates for infection
of Huh7.5 cells (see Experimental Procedures). The trend in
IC50 values of the full-length, bivalent Mab roughly reflects the
affinity trend between the monovalent Fab and isolated DIIIs
from each of the isolates but varies over a much narrower range
(1–100 nM), with IC50 ratios of 1:1, 1:50, and 1:2 among DENV-1:
DENV-2, DENV-2:DENV-3, and DENV-3:DENV-4, respectively.
As expected, neutralization by Mab 4E11 was weakest with
DENV-4, yet it was specific because an isotype-matched Mab
control at the same concentration had no effect (data not
shown). The small difference in neutralization IC50 between
DENV-3 and DENV-4 was unexpected, given the 500-fold ratio
in affinities between the corresponding recombinant DIII and
Fab 4E11.b strands A, B, and G, as well as the D-E loop, are labeled. The AG patch (see
ok’’ view of the complexes (see also Figure S1), with (G) corresponding roughly
3–314, February 8, 2012 ª2012 Elsevier Ltd All rights reserved 305
Table 1. Binding and Neutralization Data
Serotype Strain GenBank Accession No.
Fab:DIII Binding Affinity
IC50 (nM)
b IC50 (mg/ml)
bKD (nM)
a DG (kcal/mol)
DENV-1 Guiana/FGA89/1989 Q9II01 0.082 ± 0.005 13.76 ± 0.04 1.1 (0.88–1.3) 0.16
DENV-2 Jamaica/1409/1983 P07564 0.43 ± 0.04 12.79 ± 0.05 0.85 (0.59–1.2) 0.13
DENV-3 Thailand/PaH881/1988 Q98UK6 8.0 ± 1.0 11.07 ± 0.07 54 (26–110) 8.0
DENV-4 Burma/63632/1976 Unpublished 4,100 ± 700 7.36 ± 0.1 100 (65–150) 15.0
a KD values between the recombinant DIII and 4E11 Fab fragment at equilibrium in solution at 25
C, measured by competition ELISA.
bConcentration of Mab 4E11 corresponding to 50% neutralization of infection as measured by flow cytometry on huh7.5 cells. Values in parentheses
correspond to the 95% confidence range.
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For crystallization we used constructs directing periplasmic
secretion in E. coli (see Experimental Procedures) of scFv 4E11
and the recombinant DIII from each of the DENV isolates charac-
terized above (Figure 1D). The crystallization and structure deter-
mination of all four complexes are described in the Experimental
Procedures, and the resulting statistics are listed in Table 2. The
crystals of the DENV-1 DIII/scFv complex diffracted better than
the others (1.6 A˚ resolution versus 2.0–2.1 A˚, Table 2). We did
not obtain enough DIII from the DENV-3 isolate from the E. Coli
construct, and therefore, we made cocrystallization trials usingTable 2. Crystallographic Data Processing and Structure Refineme
DENV 1 DEN
Crystal Features
Space group P3121 P412
Copies of complex per asymmetric unit 1 1
Unit cell parameters
a, b, c (A˚) 110.71, 110.71, 58.32 60.4
a, b, g () 90, 90, 120 90, 9
Data Quality
Resolution (A˚)a 47.95–1.60 (1.69–1.60) 45.5
Number of observations 150,734 186,
Number of unique reflections 54,205 22,8
Completeness (%) 99.6 (99.5) 98.3
Redundancy 2.8 (2.7) 8.1 (
I/s (I) 13.9 (1.9) 23.5
Rsym (%)
a,b 4.5 (50.7) 4.6 (
Model Quality
Rwork/Rfree (%)
c 17.7/18.8 20.6
Number of protein atoms 2,561 2653
Number of solvent atoms (of which water) 354 (304) 115
Average atomic B factor for main chains/
side chains and waters (A˚2)
30.8/38.6 57.4
Rmsd in bond lengths/angles (A˚, ) 0.007/0.95 0.00
Ramachandran plot
Favored (%) 98.1 96.6
Allowed (%) 1.6 3.1
Disallowed (%) 0.3 0.3
a Values in parentheses correspond to the highest resolution shell.
b Rsym = 100 3 [
P
h
P
ijIi(h)  < I(h) > j]/
P
h
P
iIi(h), where < I(h) > is the mea
cR =
P
hjFo(h)  Fc(h)j/
P
h Fo(h), where Fo(h) and Fc(h) are the observed an
306 Structure 20, 303–314, February 8, 2012 ª2012 Elsevier Ltd All rthe dimeric DENV-3 sE ectodomain (residues 1–393, or DI-DII-
DIII) produced inDrosophilaS2 cells. Unexpectedly, the resulting
crystals contained only the scFv in complex with DENV-3 DIII,
lacking the rest of the ectodomain. SDS-PAGE analysis of the
material used for crystallization confirmed the presence, in addi-
tion to the scFv, of a protein at the expected molecular weight for
DIII (Figures S1A and S1B available online), indicating that DIII
had been cleaved from the sE dimer, presumably by a protease
contaminant. Such cleavage was not observed in samples of sE
not mixed with the scFv preparation, even when left for a long
time at 4C. Indeed, the DENV-3 sE dimer was stable and lednt
V 2 DENV 3 DENV 4
12 P21 C2221
2 1
6, 60.46, 207.46 54.06, 74.67, 86.89 106.60, 155.88, 55.91
0, 90 90, 104.49, 90 90, 90, 90
0–2.10 (2.21–2.10) 42.86–2.04 (2.15–2.04) 47.19–2.00 (2.11–2.00)
284 143,216 211,889
93 40,602 31,933
94.8 (76.0) 99.8 (98.7)
8.2) 3.5 (2.5) 6.6 (6.7)
(3.3) 10.8 (2.0) 18.5 (4.2)
56.4) 8.4 (44.4) 6.8 (44.1)
/21.4 21.8/23.4 18.1/20.8
4,860 2,505
(112) 342 (277) 326 (277)
/64.4 33.2/41.0 34.1/43.8
7/0.97 0.007/0.96 0.007/0.99
97.5 97.5
2.5 2.5
0.0 0.0
n of all observations {Ii(h)} of reflection h.
d calculated structure factor amplitudes of reflection h.
ights reserved
Figure 2. The Common Core of the 4E11 Epitopes
(A) View down the AG patch, with the molecules colored as in Figure 1E.
(B) Same as (A) but rotated by 90 about a vertical axis in the plane of the paper. The boxes in both top panels indicate the regions depicted in more detail in the
lower panels, in which the main chain is in a ‘‘worm’’ representation. Shown are the coordinates of the complex for DENV-1. Hydrogen bonds and salt bridges are
represented as black dashes (see also Figure S2.).
Structure
Determinants of Dengue Virus Cross-Neutralizationto crystals of the intact dimeric ectodomain in the absence of
scFv, the structure of which was determined in parallel (unpub-
lished data). Furthermore, the DENV-3 sE dimer was resistant
to limited proteolysis in the absence of the antibody, indicating
that binding of antibody to DIII destabilizes the dimer, likely by
leading to dimer dissociation (see below) and exposing
a segment of polypeptide N-terminal to DIII (in the DI-DIII linker),
which becomes accessible to contaminating proteases.
Overall Structure of the Immune Complexes
The complexes of scFv 4E11with DIII from each of the four DENV
isolates have, as expected, a very similar overall structure. The
4E11 variable domains are oriented with their complemen-
tarity-determining regions (CDRs) facing the A and G b strands,
which make the edge of the DIII b sandwich. The VL domain
lies above the G strand, and the VH domain rides atop the A
strand (Figure 1E). The residues in both paratope and epitope
have very similar conformations in all four complexes (Figures
1F and 1G), showing that 4E11 cross-reactivity does not involve
a significant induced fit. There are, however, differences in scFv
positioning between the complexes, especially for serotypes 3
and 4 when compared to the DENV-1 complex (Figure S1C).
The DENV-1, DENV-2, and DENV-4 DIIIs bury 900–950 A˚2 of
accessible surface area on binding the scFv, with surface com-
plementarity coefficients in the range 0.7–0.75. The apparent
buried area is smaller in the complex with DENV-3 DIII (780 A˚2)Structure 20, 30because DIII residues 362–364 (DE loop) are disordered (and
thus absent from the calculation), whereas these residues are
see contributing to the interface in the other three complexes.
The Mab 4E11 variable domains of both the heavy and light
chains share85% amino acid sequence identity with the coun-
terparts from Mab 1A1D-2. Accordingly, the complexes of
DENV-2 DIII with scFv 4E11 and Fab 1A1D-2 (PDB accession
number 2R29; Lok et al., 2008) can be superposed with
a root-mean-square deviation (rmsd) of 1.2 A˚ over 330 Ca atoms,
confirming that the epitopes of these two antibodies are
superimposable.
Determinants of 4E11Binding to andAffinity for the Four
DENV Serotypes
The list of all the intermolecular contacts in the structures of the
immune complexes of each serotype is provided in Tables S1A
and S1B. The four different 4E11 epitopes analyzed here share
a common core, located around a hydrophobic patch between
the A and G b strands, which we term the ‘‘AG patch’’ (Figures
1G and 2). This patch is part of the hydrophobic core of DIII
and consists of the side chains of residues 308, 312 (strand A)
and 387, 389, and 391 (strand G). These side chains are directed
toward the internal hydrophobic core of the DIII b sandwich but
are accessible because the A and G strands form the edge of the
b sandwich (highlighted in yellow in Figure 1G). Residues Leu387
and Trp391 are strictly conserved between DENV serotypes3–314, February 8, 2012 ª2012 Elsevier Ltd All rights reserved 307
Figure 3. Serotype-Dependent Antibody-Antigen Interactions
(A–D) Close-ups of the 4E11 paratope (left panel) and epitope (right panel) in
the complexes with DENV serotypes 1–4 as indicated. Views correspond
approximately to the boxed areas in the key in the top part of the figure, which
contain the serotype-specific residues. Semitransparent surfaces of the scFv
and DIII are colored according to their electrostatic potentials, calculated
separately for each component in the complex. The surface electrostatic
potential is represented in a color gradient from blue (basic) through white
(neutral) to red (acidic), between values of ±2kBT (where kB is the Boltzmann
constant). Salt bridges between residues in the antibody and the antigen are
shown as black dashes in the right-hand panels.
(E) The corresponding views of the interface between Fab 1A1D-2 and the
DENV-2 DIII (PDB accession number 2R29).
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substitutions that preserve the short, aliphatic character of the
side chains in the AG patch, as well as its shape (defined by
the abutting A and G strands). Indeed, the short aliphatic side
chains in the AG patch are responsible for the specificity of
Mab 4E11 for the DENV group, especially at position 389, which
in other flaviviruses is either His or Tyr. The available structures of
DIII from TBE (PDB number 1SVB), WN (1ZTX), JE (1PJW), YF
(2JV6), and Langat (2GG1) viruses show that the bulky side
chains at position 389 protrude from the patch in a way that
would prohibit 4E11 binding via steric clashes with TyrL28
(Figures 2A and S2).
Strand A of DIII presents a prominent central bulge (conserved
in all flaviviruses), located to one side of the AG patch, featuring
the conserved residues Lys310 and Glu311 (Figures 1D and 1G).
The conserved ‘‘core’’ epitope is recognized by Mab 4E11
in the same way in all four serotypes, as depicted in Figure 2:
packing against the hydrophobic side chains of the AG patch,
recognition of its shape via hydrogen bonding to the A- and
G-strand main-chain groups defining the periphery, and making
salt bridges with Lys310 and Glu311 from the central bulge. A
number of the core epitope residues identified here were previ-
ously shown, through biochemical studies, to make important
contributions to the affinity of Fab 4E11 for the DENV-1 DIII. In
particular, Lys310 was found critical for binding (Lisova et al.,
2007). Likewise, TrpH96 and GluH97 in the CDR H3 loop, which
interact with the AG patch and A-strand main-chain groups at
the center of the antibody-antigen interface, were also shown
to be essential for Fab 4E11 binding to DENV-1 DIII (Bedouelle
et al., 2006).
Serotype-Specific Contacts
The contacts of the antibody with residues in the 4E11 epitope
that are not conserved across DENV serotypes also contribute
to binding. These E residues are located on the upper portion
of DIII, which is exposed in the virion (Figure 3). The principal anti-
body residues involved in sensing these nonconserved E resi-
dues are ArgH94 (third heavy-chain framework region) and
GluL55 (CDR L2 loop). Additionally, residues Asp
H31-ThrH32,
TyrH102, and AsnL53 (Figure 1F) engage in a small number of inter-
actions with DIII residues at the periphery of the antibody-
antigen interfaces that vary between serotypes (Tables S1A
and S1B). ArgH94 and GluL55 create adjacent patches of positive
and negative electrostatic potential in the paratope. In the
complex with DENV-1 DIII (the serotype against which Mab
4E11 was raised), these residues of the paratope form salt
bridges with DIII serotype-specific residues Glu309 and Lys307,
respectively (Figures 1D and 3A). Binding to DIII from the other
serotypes is facilitated by conformational variability of the
ArgH94 side chain and changes in overall antibody positioning,
allowing the partial conservation of charge complementarity
despite amino acid sequence variations between serotypes
over this region (Figures 1D and 3B–3D). This is particularly
striking for the complex with DIII from the DENV-3 isolate.
Here, the antibody shifts down such that GluL55 and ArgH94
face the DIII B strand (which is antiparallel to strand A; see
Figures 1B and 1G) and interact with Lys327 and Glu325,
mimicking the interactions with the DENV-1 A-strand residues
Lys307 and Glu309 (Figure 3C). Finally, the absence of a basic
residue at positions 307 or 327 in DENV-4 DIII results inights reserved
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Determinants of Dengue Virus Cross-Neutralizationamuch lower degree of charge complementarity across the anti-
body-antigen interface than in the complexes with the other
serotypes (Figure 3D), reflecting the much lower affinity of Fab
4E11 for DENV-4 DIII (Table 1).
Previous mutagenesis studies on the DENV-1 DIII A and G
strands showed that mutation of residue Lys307 to alanine
reduced the free energy of dissociation (DGd) of Fab 4E11 from
13.8 to 9.7 kcal/mol (Lisova et al., 2007), which was the
second-greatest reduction in affinity after mutation of the
conserved Lys310. This suggests that the effect of truncating
the Lys307 side chain in the DENV-1 DIII accounts for the
majority of the difference in DGd of Fab 4E11 binding to DENV-1
and DENV-4 DIIIs (Table 1). Likewise, the DGd value of
12.8 kcal/mol for the DENV-2 DIII (Table 1), compared with
12.5 kcal/mol for the DENV-1 DIII Glu309Ala mutant (Lisova
et al., 2007), shows that elimination of the negative charge at
position 309 appears to account for the affinity difference of
Fab 4E11 for the DENV-2 DIII versus that of DENV-1. Residue
changes at positions 309 and 307 are thus the main determi-
nants of the affinities of Fab 4E11 for the DENV-2 and DENV-4
DIIIs compared with that of DENV-1. The ability of the B-strand
residues Glu325 and Lys327 of DENV-3 to mimic these interac-
tions, despite having unfavorable A-strand residues at these
locations, is likely to be crucial in maintaining high-affinity
binding to this serotype. Previous biochemical studies have
shown that cross-reactive murineMabs binding to A-strand resi-
dues on the DENV-2 DIII commonly have epitope determinants
on the B strand of the DENV-3 DIII (Gromowski et al., 2008;
Matsui et al., 2009). These observations are a strong indication
that the strand-switching mechanism of 4E11 cross-reactivity
with DENV-3 that we describe here is a general feature of all
A-strand Mabs.
The contacts observed here between scFv 4E11 and the
DENV-2 DIII are mostly conserved in the corresponding complex
of Fab 1A1D-2. However, an important difference is that 1A1D-2
has an aspartic acid at position H95 in its CDRH3 loop that forms
an additional salt bridge with Lys307, whereas the corresponding
residue in 4E11 is glycine. As a result, the 1A1D-2 paratope is
significantly more negatively charged than that of 4E11 (Fig-
ure 3E). This presumably reflects the fact that 4E11 and 1A1D-2
were raised against DENV-1 and DENV-2 strains, respectively,
which have different charge distributions along the A strand
(because the residue at position 309 is glutamate in DENV-1
and valine in DENV-2). As an additional consequence, the
1A1D-2 paratope displays an even lower charge complemen-
tarity with DENV-4 DIII than that of 4E11 (Figures 3D and 3E).
These observations explain the differing serotype dependence
of neutralization between these two antibodies, and in particular
why Mab 4E11 neutralizes DENV-4 strains at moderate antibody
titers, whereas Mab 1A1D-2 does not.
Molecular Basis for Immunodominance of the DENV DIII
A Strand in Mice
Analysis of themurine germline shows that the 4E11 and 1A1D-2
variable domains are both derived from the same heavy- and
light-chain variable (V) and junction (J) gene segments, but
different diversity (D) segments (see Experimental Procedures).
In both antibodies, almost all residues that contact DIII are pre-
sent in the germline sequences of the relevant gene segmentsStructure 20, 30(Figures 4A and 4B). In both cases, VDJ recombination has
resulted in CDR H3 loops with identical lengths (six residues),
with a glutamate at H97 and an aromatic side chain at position
H96 (Trp in 4E11 and Tyr in 1A1D-2) that plug the center of the
antibody-antigen interface (Figures 2, 4C,and 4D). The only
significant difference is the residue at position H95 (glycine in
4E11 and aspartic acid in 1A1D-2), which dictates the differing
serotype responses of these antibodies as discussed above.
Of the 14 known murine D segments, 6 would be capable of
forming 1A1D-2/4E11-like H3 loops (Figure 4E). This, in conjunc-
tion with the inherent capacity of the V gene segments utilized by
4E11 and 1A1D-2 to form high-affinity interactions with DIII resi-
dues that are conserved among all four serotypes, may explain
the immunodominance of A-strand epitopes in mice. Amino
acid sequence variations at position H95, arising from N regions
or somatic hypermutations, could then generate a family of
cross-reactive Mabs with distinct avidity and neutralization
profiles by serotype. In summary this analysis shows that the
murine germline harbors gene segments with an inherent
capacity for high-affinity binding to DIII from all four DENV sero-
types. This is in line with the observation that most strongly
neutralizing murine Mabs against DENV bind to DIII, whereas
humans do not appear to make such antibodies as readily (Crill
et al., 2009; Oliphant et al., 2007; Wahala et al., 2009). However,
the memory B cell pool of DENV-infected humans does contain
clones that encode anti-DIII antibodies capable of neutralizing
multiple DENV serotypes (Beltramello et al., 2010), and a recent
experimentally validated computational docking study indicates
that these antibodies bind to A-strand epitopes that include
residue Lys310 (Simonelli et al., 2010).
Insights into the Neutralization Mechanism of Murine
A-Strand Mabs
The crystal structures of the prefusion DENV sE dimers (Modis
et al., 2003, 2005; Zhang et al., 2004) show that the DIII A strand
forms one side of the pocket that accommodates residue Trp101
from the fusion loop of the partner subunit in the dimer. The roof
of this pocket is formed by the side chain of DIII residue Lys310,
which stacks against the side chain of Trp101 of the opposite
subunit (Figure 5A). Lys310 is thus involved in intradimer contacts
and is also a critical epitope residue for Mabs 4E11, 1A1D-2,
9D12, and every other known A-strand Mab for which mutagen-
esis studies of the antigen have been made (Gromowski et al.,
2008, 2010; Lisova et al., 2007; Matsui et al., 2009; Shrestha
et al., 2010; Sukupolvi-Petty et al., 2007; Thullier et al., 2001).
Not surprisingly, docking our atomic model for the DIII/4E11
complex onto the structures of the corresponding sE dimers
shows that there is a partial clash between the 4E11 CDR H2
loop and the apposed fusion loop in the dimer, as illustrated in
Figure 5B. This incompatibility between dimer contacts and
binding of A-strand antibodies is in keeping with our observa-
tions that 4E11 scFv led to DENV-3 sE dimer instability and
cleavage at the DI-DIII linker. This cleavage is likely to follow
dimer dissociation because experiments of limited proteolysis
showed that the sE dimer is relatively resistant to degradation,
as mentioned above.
Because the E dimers are the building blocks of the mature
flavivirus particles, dimer dissociation upon binding of A-strand
antibodies will induce a major rearrangement of the virion3–314, February 8, 2012 ª2012 Elsevier Ltd All rights reserved 309
Figure 4. Immunodominance of the DIII A Strand
(A and B) Genetic origin of the residues in the 4E11 (A) and 1A1D-2 (B) variable domains (heavy-chain and light-chain colored black and white, respectively) that
contact DIII in their respective complexes. The side chains contacting DIII are shown as sticks with carbon atoms colored yellow and magenta for conserved and
nonconserved residues within the murine germline, respectively.
(C andD)Models of VDJ recombination giving rise to theH3 loops of 4E11 (C) and 1A1D-2 (D). In (C) the nucleotide sequences of the 3
0 and 50 ends of the VH and JH
gene segments at either side of the junction, and the entire D segment, are aligned against the 4E11 nucleotide sequence (Bedouelle et al., 2006). Nucleotides
conserved with 4E11 are written in bold capital letters. N/SH shows nucleotides added by the terminal deoxynucleotidyl transferase during VDJ joining, or
generated by subsequent somatic hypermutations—these are written in lowercase bold letters at the appropriate positions along the sequence. The amino acid
sequence of the 4E11 H3 loop is shown in single-letter code at the bottom. Residues arising from N regions or somatic hypermutations are underlined, and are
additionally written in magenta if they contact DIII. In (D), because the nucleotide sequence of Mab 1A1D-2 is not published, our analysis of VDJ recombination is
based on amino acid sequence comparisons, and the nucleotide sequence shown in the figure is hypothetical. Several VDJ recombination schemes are possible
as a result of the degeneracy within the murine SP2 family of D segments (see E)—shown here is one example. In both (C) and (D), the TGGGA and TA(T/C)GA
nucleotide sequences from the D segments that give rise to the Trp/Tyr-Glu sequences in the 4E11 and 1A1D-2 H3 loops (in conjunction with the addition of a G
nucleotide at the 30 end) are written in green.
(E) Nucleotide sequences of the 14 known murine D segments (taken from the IMGT website). The TGGGA and TA(T/C)GA sequences are written in bold green
uppercase letters.
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Determinants of Dengue Virus Cross-Neutralizationsurface, as shown earlier by cryo-EM studies on Fab 1A1D-2
bound to the DENV-2 virion (Lok et al., 2008). This is also in
line with binding competition assays with DENV virions showing
that prior binding of the A-strand Mab 9D12 (Sukupolvi-Petty
et al., 2007) promotes the binding of antibodies against the
fusion loop (Henchal et al., 1985). Indeed, the epitopes of the
latter antibodies are poorly accessible on mature virions
because they are partially buried at the dimer interface (Stiasny
et al., 2006). These observations suggest that disruption of the
mature virion architecture and premature exposure of the fusion
loop is a general feature of antibodies binding to the A-strand
epitope. Indeed, binding of A-strand Mabs to mature particles
was proposed to disrupt the virion architecture by capturing
thermally deformed states of the glycoprotein shell and prevent-
ing their relaxation back to the equilibrium ‘‘herringbone’’
arrangement of E dimers of the unbound virus (Lok et al.,310 Structure 20, 303–314, February 8, 2012 ª2012 Elsevier Ltd All r2008). Disruption of the mature virion architecture is likely to be
irreversible, even upon dissociation of the antibody from the
virus. If so, then the neutralization potency of A-strand Mabs
such as 4E11 would be determined not by their avidities for the
virion but rather their rates of association (kon) and the incubation
time. Also, as suggested by Lok et al. (2008), the tight packing of
E dimers on the virions is such that binding to one of the 180 E
subunits may propagate the conformational change in the
particle, exposing the fusion loops and inactivating the virions
by aggregation via the exposed fusion loops. In such a model,
once the thermal motion allowed the binding to one of the
180 E subunits at the virion surface, the particle distortion would
propagate to induce disruption of additional dimers, allowing
more antibodies to bind. The observation that Fab binding was
marginal at 4C—temperature at which the majority of particles
had no bound Fab, but the few that were bound were saturatedights reserved
Figure 5. Role of 4E11 Epitope Residues in sE
Dimer Contacts
(A) The side-chain Trp101 (green) at the tip of the fusion
loop (in green) of one E subunit in the dimer, which is the
building block of the icosahedral glycoprotein shell, is
buried at the DI/DIII interface (red/blue) of its dimer mate
(PDB accession number 1OKE; Modis et al., 2003). The
molecular surface of the 4E11 epitope is semitransparent.
Note the location of the Lys101 side chain, stabilizing this
intersubunit interaction with Trp101.
(B) Docking of scFv 411 (color coded as in the previous
figures) from its complex with the DENV-2 DIII onto the
crystal structure of the DENV-2 sE dimer. Note the clash
between the tip of the H2 loop and the fusion loop of the
partner E subunit in the dimer.
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Determinants of Dengue Virus Cross-Neutralizationwith Fab (Lok et al., 2008)—is in support of this hypothesis. The
relatively small difference in neutralization IC50 of Mab 4E11
across DENV serotypes when compared to the difference in
the respective binding affinity of its Fab fragment for the exposed
epitope in isolated DIII also supports this view (Table 1). Recent
data have shown that antibodies against flaviviruses—WN virus
and DENV—increase their neutralization capacity when left to
interact for longer periods of time (Dowd et al., 2011). This
suggests that even antibodies that bind poorly (such as 4E11
binding to DENV-4 particles) will lead to inactivation of the virion
if left to interact for long enough. Our data, however, suggest
a threshold level in affinity from which the antibody jumps from
efficient neutralization to relatively poor neutralization. This is
exemplified in Table 1 by the fact that, despite having 500-fold
higher affinity for DENV-3 than for DENV-4 DIII, 4E11 displays
only a 2-fold increase in neutralization efficiency (IC50). In
contrast the 20-fold increase in affinity between DENV-2 and
DENV-3 DIII and 4E11 leads to a 50-fold increase in neutraliza-
tion efficiency (i.e., an IC50 50 times lower). These values would
suggest that the threshold is likely to lie in the range between
0.5 and 5 nM Fab/DIII binding affinity. However, this estimate
does not take into account possible differences in the breathing
rate of DENV particles from different strains, which may
strongly affect the neutralization kinetics, further illustrating the
complexity of this process.
Biological Implications
Are there implications of the presence of the exposed, cross-
reactive A-strand epitope for identifying the region of DIII postu-
lated to be responsible for receptor binding? The identification of
the DENV receptors is difficult likely because it may involve
low-affinity interactions at the cell surface. However, if all four
DENV serotypes recognize the same receptor, then it is possible
that certain features of the DIII surface are maintained, which
make recognition by 4E11 possible, while still being restricted
to theDENVgroup. TheA-strand epitope is, therefore, a plausible
candidate surface for interaction with receptor. If this is con-
firmed, a new question is: Does interaction with receptor have
the same effect on the particle as do A-strand antibodies?
Such an effect would mean that the particle exposes the fusion
loop already at the plasmamembrane of the infected cell, making
the interaction irreversible, and explaining why the initial interac-
tions may require only low affinity. A similar process was sug-Structure 20, 30gested for alphaviruses, with the exposure of ‘‘transitional’’
epitopes in glycoprotein E2 described for Sindbis virus, which
become accessible only upon incubation of the virion at 37C
with susceptible cells (Meyer and Johnston, 1993). The crystal
structure of the alphavirus E2/E1 heterodimer (Voss et al., 2010)
showed that the fusion loop of E1, which is homologous to flavi-
virus E, lies in a groove of E2. The transitional epitopemaps to this
groove, indicating that exposure of this epitope can only take
place upon exposure of the fusion loop at the cell surface, which
makes binding to cells irreversible. Understanding whether
receptor binding by flaviviruses and alphaviruses is merely
a passive event, allowing particle uptake to be disassembled in
the endosome upon exposure to low pH, or whether the receptor
has a more active role, inducing partial particle disassembly,
remains an important issue to be further investigated.
EXPERIMENTAL PROCEDURES
Cells, Viruses, and Monoclonal Antibodies
Mosquito AP61 cells and confluent human hepatocyte (Huh 7.5) cells were
prepared as described in the Supplemental Experimental Procedures. The
virus strains used throughout this work are listed in Table 1. Virus stocks
were grown in AP61 cells, purified from supernatants by ultracentrifugation,
and titered as described in the Supplemental Experimental Procedures. Mab
4E11 (IgG2a/k) was produced and purified from hybridoma cells as previously
described (Thullier et al., 1999, 2001). Mab 2H2, a murine antibody binding to
protein prM of all four dengue serotypes, was affinity purified from hybridoma
cells obtained from ATCC (reference HB-114).
Neutralization Assays
Each virus strain (at 4.5 3 105 pfu/ml for DENV-1, DENV-3, and DENV-4;
2.25 3 106 pfu/ml for DENV-2) was incubated with 10-fold serial dilutions of
Mab 4E11 at 37C for 2 hr in medium (DMEM containing 2% FCS, 1% peni-
cillin, and 1% streptomycin), and added to 80% confluent Huh 7.5 cells at
moi values of 0.1 for DENV-1, 5.0 for DENV-2, and 0.5 for DENV-3/DENV-4.
Each concentration was tested in duplicate. An isotype-matched control
murine Mab was used as well. Infection was allowed to proceed for 2 hr at
37C before the virus/Mab mixtures were removed and the cells washed.
The infected cell cultures were made up to 1 ml vol in medium and left at
37C for 24 hr. They were transferred to 96-well plates and fixed and permea-
bilized using the Cytofix/Cytoperm kit (BD Biosciences). Cells were stained
using 10 mg/ml Mab 2H2 for 1 hr at 4C, and a phycoerythrin-conjugated
goat anti-mouse secondary antibody (Santa Cruz Biotechnology; RO480) at
1:500 dilution for 30 min at 4C. Cells were analyzed using a BD FACScalibur
instrument. The percentage of infected cells was determined using the FlowJo
software package. IC50 values were determined by fitting dose-response
curves to these data using the Prism software package.3–314, February 8, 2012 ª2012 Elsevier Ltd All rights reserved 311
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Determinants of Dengue Virus Cross-NeutralizationBinding-Affinity Measurements
The dissociation constant (KD) values at equilibrium in solution at 25
C
between recombinant Fab 4E11 and DIIIs were measured by competition
ELISA as described previously (Lisova et al., 2007).
Protein Expression, Purification, and Crystallization
Recombinant, His-tagged Fab 4E11, scFv 4E11, and DIII from serotypes 1, 2,
and 4 were expressed and purified from E. coli periplasmic extracts using
nickel-ion affinity chromatography as described previously (Bedouelle et al.,
2006; Lisova et al., 2007; Renard et al., 2003). Protein expression was opti-
mized in microfermentors and scaled up to a 4 liter fermentor in high-density
medium (Frachon et al., 2006) at the Protein Production Facility of Institut
Pasteur. The protein samples were further purified by size-exclusion chroma-
tography using a Superdex 75 10/30 column (GE Healthcare) in 150 mM NaCl
and 20 mM Tris-HCl (pH 8.0). Pure fractions were pooled and concentrated to
15 mg/ml in 50 mM NaCl and 5 mM Tris-HCl (pH 8.0). The DENV-3 sE ectodo-
main (strain PaH881/88) was produced in Drosophila cells, and purified by
affinity and size-exclusion chromatography (see Supplemental Experimental
Procedures). Purified DENV-3 sE was concentrated to 12 mg/ml in 50 mM
NaCl and 25 mM Tris-HCl (pH 8.0). Concentrated scFv and DIII preparations
were mixed to give a 1:1 stoichiometry, except for serotype 4 (1:1.5), and total
protein concentrations of 14–16 mg/ml. Concentrated scFv and DENV-3 sE
were mixed to give a 1:1 stoichiometry and a total protein concentration of
13 mg/ml. In all cases these mixtures were incubated at 4C overnight and
used for crystallization trials without further purification the following day.
Crystallization conditions were screened by robot at 19C in 96-well sitting
drop format (0.2 ml of protein with an equal volume of precipitant per drop).
The crystals were cryoprotected prior to cryo-cooling in liquid nitrogen. Table
S2 details the crystallization and cryo-cooling conditions for structure
determination.
Structure Determination and Refinement
Data were collected at the Swiss Light Source beamline PX1 using the Pilatus
6M detector. Data were processed with XDS (Kabsch, 1988) and scaled and
reduced with SCALA (Evans, 1993) and other CCP4 programs (Collaborative
Computational Project, Number 4, 1994). The X-ray data were phased by
molecular replacement with Phaser (McCoy et al., 2007), using the crystal
structure of scFv 1F9 (PDB accession number 1DZB), DIII from previously pub-
lished DENV-2 and DENV-3 sE crystal structures (1OAN and 1UZG, respec-
tively), and the solution NMR structure of the DENV-4 DIII (2H0P) as search
models.Structureswere visualized and rebuilt usingCoot (Emsley andCowtan,
2004) and refined with BUSTER (Bricogne, 1993) with the heavy chain, light
chain, and DIII defined as individual TLS groups. Water molecules were added
automatically during the later stages of refinement and verified manually.
Structure Analysis
Structural superpositions, buried surface area and surface complementarity
coefficient calculations, and intermolecular contacts were calculated using
LSQKAB, AREAIMOL, SC, and NCONT from the CCP4 suite. Figures were
prepared in PyMOL (http://pymol.sourceforge.net). Electrostatic potentials
were calculated using the APBS suite (Baker et al., 2001). Structures were vali-
dated using theMolProbity web server (http://molprobity.biochem.duke.edu/).
Sequence Analysis of Mabs 4E11 and 1A1D-2
The murine germline gene segments from which Mab 4E11 derives have
already been reported (Bedouelle et al., 2006). The VH and VL germline
segments of Mab 1A1D-2 were identified with the IMGT/DomainGapAlign
tool of the IMGT website (http://www.imgt.org). Its JH and JL germline
segments were identified by aligning its sequence with the translations of
the 10 IGKJ and 8 IGHJ existing germline segments. Finally, its D region, which
contains at most four residues (DYEG), was compared with the translations of
the existing IGHD alleles.
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